Risdiplam
Back to searchMolecule Structure
Scientific Name
Risdiplam
Description of the Drug
Risdiplam is an oral mRNA splicing modifier used in the treatment of spinal muscular atrophy (SMA).
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB15305
http://www.drugbank.ca/drugs/DB15305
Brand Name(s)
Evrysdi
Company Owner(s)
Genentech Inc
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
SMN2 pre-mRNA | NUCLEIC-ACID | POSITIVE MODULATOR | CHEMBL3826841 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL17260852 |
Human Metabolome Database | HMDB0304853 |
DrugBank | DB15305 |
PubChem | 118513932 |
DrugCentral | 5407 |
ChemicalBook | CB64674494 |
Guide to Pharmacology | 11170 |
rxnorm | RISDIPLAM |